nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP1B1—Mitoxantrone—lymphatic system cancer	0.162	0.223	CbGbCtD
Lansoprazole—ABCG2—Teniposide—lymphatic system cancer	0.11	0.152	CbGbCtD
Lansoprazole—ABCG2—Mitoxantrone—lymphatic system cancer	0.0771	0.106	CbGbCtD
Lansoprazole—CYP1A2—Carmustine—lymphatic system cancer	0.0676	0.093	CbGbCtD
Lansoprazole—ABCG2—Vincristine—lymphatic system cancer	0.0531	0.073	CbGbCtD
Lansoprazole—CYP2C19—Teniposide—lymphatic system cancer	0.0493	0.0677	CbGbCtD
Lansoprazole—CYP2C9—Teniposide—lymphatic system cancer	0.041	0.0563	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—lymphatic system cancer	0.0321	0.0442	CbGbCtD
Lansoprazole—ABCB1—Mitoxantrone—lymphatic system cancer	0.0278	0.0382	CbGbCtD
Lansoprazole—CYP3A4—Cytarabine—lymphatic system cancer	0.0242	0.0332	CbGbCtD
Lansoprazole—CYP3A4—Teniposide—lymphatic system cancer	0.0238	0.0328	CbGbCtD
Lansoprazole—ABCB1—Vincristine—lymphatic system cancer	0.0191	0.0263	CbGbCtD
Lansoprazole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0167	0.0229	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—lymphatic system cancer	0.0116	0.0159	CbGbCtD
Lansoprazole—CYP3A4—Vincristine—lymphatic system cancer	0.0115	0.0158	CbGbCtD
Lansoprazole—Agitation—Carmustine—lymphatic system cancer	0.000249	0.000913	CcSEcCtD
Lansoprazole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000248	0.000909	CcSEcCtD
Lansoprazole—Asthenia—Fludarabine—lymphatic system cancer	0.000248	0.000909	CcSEcCtD
Lansoprazole—Rash—Teniposide—lymphatic system cancer	0.000248	0.000909	CcSEcCtD
Lansoprazole—Dermatitis—Teniposide—lymphatic system cancer	0.000248	0.000908	CcSEcCtD
Lansoprazole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000247	0.000904	CcSEcCtD
Lansoprazole—Headache—Teniposide—lymphatic system cancer	0.000246	0.000903	CcSEcCtD
Lansoprazole—Pruritus—Fludarabine—lymphatic system cancer	0.000244	0.000896	CcSEcCtD
Lansoprazole—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000244	0.000895	CcSEcCtD
Lansoprazole—Back pain—Mitoxantrone—lymphatic system cancer	0.000244	0.000893	CcSEcCtD
Lansoprazole—Leukopenia—Carmustine—lymphatic system cancer	0.000243	0.000889	CcSEcCtD
Lansoprazole—Anorexia—Bleomycin—lymphatic system cancer	0.000242	0.000885	CcSEcCtD
Lansoprazole—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00024	0.000878	CcSEcCtD
Lansoprazole—Anaemia—Vincristine—lymphatic system cancer	0.000239	0.000876	CcSEcCtD
Lansoprazole—Agitation—Vincristine—lymphatic system cancer	0.000238	0.000871	CcSEcCtD
Lansoprazole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000237	0.00087	CcSEcCtD
Lansoprazole—Polyuria—Methotrexate—lymphatic system cancer	0.000237	0.00087	CcSEcCtD
Lansoprazole—Photosensitivity—Methotrexate—lymphatic system cancer	0.000237	0.00087	CcSEcCtD
Lansoprazole—Hypotension—Bleomycin—lymphatic system cancer	0.000237	0.000868	CcSEcCtD
Lansoprazole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000236	0.000867	CcSEcCtD
Lansoprazole—Convulsion—Carmustine—lymphatic system cancer	0.000235	0.000861	CcSEcCtD
Lansoprazole—Hypertension—Carmustine—lymphatic system cancer	0.000234	0.000858	CcSEcCtD
Lansoprazole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000234	0.000857	CcSEcCtD
Lansoprazole—Nausea—Teniposide—lymphatic system cancer	0.000234	0.000856	CcSEcCtD
Lansoprazole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000233	0.000854	CcSEcCtD
Lansoprazole—Vertigo—Vincristine—lymphatic system cancer	0.000232	0.000852	CcSEcCtD
Lansoprazole—Leukopenia—Vincristine—lymphatic system cancer	0.000232	0.000849	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000231	0.000846	CcSEcCtD
Lansoprazole—Chest pain—Carmustine—lymphatic system cancer	0.000231	0.000846	CcSEcCtD
Lansoprazole—Myalgia—Carmustine—lymphatic system cancer	0.000231	0.000846	CcSEcCtD
Lansoprazole—Anxiety—Carmustine—lymphatic system cancer	0.00023	0.000843	CcSEcCtD
Lansoprazole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000227	0.000834	CcSEcCtD
Lansoprazole—Malaise—Mitoxantrone—lymphatic system cancer	0.000227	0.000833	CcSEcCtD
Lansoprazole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000226	0.000828	CcSEcCtD
Lansoprazole—Renal failure acute—Methotrexate—lymphatic system cancer	0.000226	0.000828	CcSEcCtD
Lansoprazole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000225	0.000827	CcSEcCtD
Lansoprazole—Convulsion—Vincristine—lymphatic system cancer	0.000224	0.000822	CcSEcCtD
Lansoprazole—Hypertension—Vincristine—lymphatic system cancer	0.000223	0.000819	CcSEcCtD
Lansoprazole—Confusional state—Carmustine—lymphatic system cancer	0.000223	0.000817	CcSEcCtD
Lansoprazole—Oedema—Carmustine—lymphatic system cancer	0.000221	0.000811	CcSEcCtD
Lansoprazole—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000221	0.00081	CcSEcCtD
Lansoprazole—Decreased appetite—Bleomycin—lymphatic system cancer	0.00022	0.000807	CcSEcCtD
Lansoprazole—Myalgia—Vincristine—lymphatic system cancer	0.00022	0.000807	CcSEcCtD
Lansoprazole—Cough—Mitoxantrone—lymphatic system cancer	0.00022	0.000806	CcSEcCtD
Lansoprazole—Infection—Carmustine—lymphatic system cancer	0.00022	0.000805	CcSEcCtD
Lansoprazole—Vomiting—Fludarabine—lymphatic system cancer	0.00022	0.000805	CcSEcCtD
Lansoprazole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000218	0.0008	CcSEcCtD
Lansoprazole—Rash—Fludarabine—lymphatic system cancer	0.000218	0.000799	CcSEcCtD
Lansoprazole—Dermatitis—Fludarabine—lymphatic system cancer	0.000218	0.000798	CcSEcCtD
Lansoprazole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000217	0.000797	CcSEcCtD
Lansoprazole—Pain—Bleomycin—lymphatic system cancer	0.000217	0.000794	CcSEcCtD
Lansoprazole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000217	0.000794	CcSEcCtD
Lansoprazole—Headache—Fludarabine—lymphatic system cancer	0.000216	0.000794	CcSEcCtD
Lansoprazole—Tachycardia—Carmustine—lymphatic system cancer	0.000216	0.000791	CcSEcCtD
Lansoprazole—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000215	0.000789	CcSEcCtD
Lansoprazole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000214	0.000786	CcSEcCtD
Lansoprazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000214	0.000786	CcSEcCtD
Lansoprazole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000214	0.000786	CcSEcCtD
Lansoprazole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000214	0.000783	CcSEcCtD
Lansoprazole—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000213	0.00078	CcSEcCtD
Lansoprazole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000212	0.000777	CcSEcCtD
Lansoprazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000211	0.000774	CcSEcCtD
Lansoprazole—Oedema—Vincristine—lymphatic system cancer	0.000211	0.000774	CcSEcCtD
Lansoprazole—Anorexia—Carmustine—lymphatic system cancer	0.000211	0.000773	CcSEcCtD
Lansoprazole—Infection—Vincristine—lymphatic system cancer	0.00021	0.000769	CcSEcCtD
Lansoprazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000209	0.000765	CcSEcCtD
Lansoprazole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000208	0.000764	CcSEcCtD
Lansoprazole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000207	0.00076	CcSEcCtD
Lansoprazole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000207	0.000759	CcSEcCtD
Lansoprazole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000207	0.000758	CcSEcCtD
Lansoprazole—Hypotension—Carmustine—lymphatic system cancer	0.000207	0.000758	CcSEcCtD
Lansoprazole—Oedema—Mitoxantrone—lymphatic system cancer	0.000206	0.000754	CcSEcCtD
Lansoprazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000206	0.000754	CcSEcCtD
Lansoprazole—Nausea—Fludarabine—lymphatic system cancer	0.000205	0.000752	CcSEcCtD
Lansoprazole—Infection—Mitoxantrone—lymphatic system cancer	0.000204	0.000749	CcSEcCtD
Lansoprazole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000204	0.000748	CcSEcCtD
Lansoprazole—Shock—Mitoxantrone—lymphatic system cancer	0.000202	0.000741	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000201	0.000739	CcSEcCtD
Lansoprazole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000201	0.000738	CcSEcCtD
Lansoprazole—Urticaria—Bleomycin—lymphatic system cancer	0.000201	0.000738	CcSEcCtD
Lansoprazole—Anorexia—Vincristine—lymphatic system cancer	0.000201	0.000738	CcSEcCtD
Lansoprazole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000201	0.000736	CcSEcCtD
Lansoprazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.0002	0.000734	CcSEcCtD
Lansoprazole—Insomnia—Carmustine—lymphatic system cancer	0.0002	0.000733	CcSEcCtD
Lansoprazole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.0002	0.000732	CcSEcCtD
Lansoprazole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000199	0.000729	CcSEcCtD
Lansoprazole—Paraesthesia—Carmustine—lymphatic system cancer	0.000199	0.000728	CcSEcCtD
Lansoprazole—Mood swings—Methotrexate—lymphatic system cancer	0.000197	0.000724	CcSEcCtD
Lansoprazole—Hypotension—Vincristine—lymphatic system cancer	0.000197	0.000723	CcSEcCtD
Lansoprazole—Dyspnoea—Carmustine—lymphatic system cancer	0.000197	0.000723	CcSEcCtD
Lansoprazole—Somnolence—Carmustine—lymphatic system cancer	0.000197	0.000721	CcSEcCtD
Lansoprazole—Anorexia—Mitoxantrone—lymphatic system cancer	0.000196	0.000718	CcSEcCtD
Lansoprazole—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000192	0.000705	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000192	0.000705	CcSEcCtD
Lansoprazole—Decreased appetite—Carmustine—lymphatic system cancer	0.000192	0.000705	CcSEcCtD
Lansoprazole—Hypotension—Mitoxantrone—lymphatic system cancer	0.000192	0.000704	CcSEcCtD
Lansoprazole—Insomnia—Vincristine—lymphatic system cancer	0.000191	0.0007	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000191	0.0007	CcSEcCtD
Lansoprazole—Paraesthesia—Vincristine—lymphatic system cancer	0.00019	0.000695	CcSEcCtD
Lansoprazole—Constipation—Carmustine—lymphatic system cancer	0.000189	0.000693	CcSEcCtD
Lansoprazole—Pain—Carmustine—lymphatic system cancer	0.000189	0.000693	CcSEcCtD
Lansoprazole—Breast disorder—Methotrexate—lymphatic system cancer	0.000188	0.00069	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000188	0.000688	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000187	0.000687	CcSEcCtD
Lansoprazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000187	0.000684	CcSEcCtD
Lansoprazole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000185	0.000677	CcSEcCtD
Lansoprazole—Decreased appetite—Vincristine—lymphatic system cancer	0.000184	0.000673	CcSEcCtD
Lansoprazole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000183	0.000672	CcSEcCtD
Lansoprazole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000183	0.00067	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000182	0.000668	CcSEcCtD
Lansoprazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000182	0.000668	CcSEcCtD
Lansoprazole—Fatigue—Vincristine—lymphatic system cancer	0.000182	0.000667	CcSEcCtD
Lansoprazole—Asthenia—Bleomycin—lymphatic system cancer	0.000182	0.000666	CcSEcCtD
Lansoprazole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000181	0.000663	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000181	0.000663	CcSEcCtD
Lansoprazole—Constipation—Vincristine—lymphatic system cancer	0.000181	0.000662	CcSEcCtD
Lansoprazole—Pain—Vincristine—lymphatic system cancer	0.000181	0.000662	CcSEcCtD
Lansoprazole—Asthma—Methotrexate—lymphatic system cancer	0.00018	0.00066	CcSEcCtD
Lansoprazole—Pruritus—Bleomycin—lymphatic system cancer	0.000179	0.000657	CcSEcCtD
Lansoprazole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000179	0.000655	CcSEcCtD
Lansoprazole—Eosinophilia—Methotrexate—lymphatic system cancer	0.000178	0.000654	CcSEcCtD
Lansoprazole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000177	0.00065	CcSEcCtD
Lansoprazole—Pancreatitis—Methotrexate—lymphatic system cancer	0.000177	0.000647	CcSEcCtD
Lansoprazole—Pain—Mitoxantrone—lymphatic system cancer	0.000176	0.000644	CcSEcCtD
Lansoprazole—Constipation—Mitoxantrone—lymphatic system cancer	0.000176	0.000644	CcSEcCtD
Lansoprazole—Abdominal pain—Carmustine—lymphatic system cancer	0.000175	0.000641	CcSEcCtD
Lansoprazole—Body temperature increased—Carmustine—lymphatic system cancer	0.000175	0.000641	CcSEcCtD
Lansoprazole—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000173	0.000633	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000173	0.000633	CcSEcCtD
Lansoprazole—Pancytopenia—Methotrexate—lymphatic system cancer	0.000171	0.000627	CcSEcCtD
Lansoprazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000169	0.000621	CcSEcCtD
Lansoprazole—Neutropenia—Methotrexate—lymphatic system cancer	0.000168	0.000617	CcSEcCtD
Lansoprazole—Dysuria—Methotrexate—lymphatic system cancer	0.000168	0.000617	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000168	0.000616	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000167	0.000614	CcSEcCtD
Lansoprazole—Body temperature increased—Vincristine—lymphatic system cancer	0.000167	0.000612	CcSEcCtD
Lansoprazole—Abdominal pain—Vincristine—lymphatic system cancer	0.000167	0.000612	CcSEcCtD
Lansoprazole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000166	0.000608	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000164	0.000603	CcSEcCtD
Lansoprazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000163	0.000599	CcSEcCtD
Lansoprazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000163	0.000597	CcSEcCtD
Lansoprazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000163	0.000596	CcSEcCtD
Lansoprazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000163	0.000596	CcSEcCtD
Lansoprazole—Pneumonia—Methotrexate—lymphatic system cancer	0.000162	0.000592	CcSEcCtD
Lansoprazole—Vomiting—Bleomycin—lymphatic system cancer	0.000161	0.000591	CcSEcCtD
Lansoprazole—Infestation—Methotrexate—lymphatic system cancer	0.000161	0.000589	CcSEcCtD
Lansoprazole—Infestation NOS—Methotrexate—lymphatic system cancer	0.000161	0.000589	CcSEcCtD
Lansoprazole—Rash—Bleomycin—lymphatic system cancer	0.00016	0.000586	CcSEcCtD
Lansoprazole—Dermatitis—Bleomycin—lymphatic system cancer	0.00016	0.000585	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000159	0.000584	CcSEcCtD
Lansoprazole—Asthenia—Carmustine—lymphatic system cancer	0.000159	0.000582	CcSEcCtD
Lansoprazole—Renal failure—Methotrexate—lymphatic system cancer	0.000158	0.000579	CcSEcCtD
Lansoprazole—Stomatitis—Methotrexate—lymphatic system cancer	0.000157	0.000574	CcSEcCtD
Lansoprazole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000156	0.000572	CcSEcCtD
Lansoprazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000156	0.00057	CcSEcCtD
Lansoprazole—Sweating—Methotrexate—lymphatic system cancer	0.000154	0.000564	CcSEcCtD
Lansoprazole—Haematuria—Methotrexate—lymphatic system cancer	0.000153	0.000561	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000152	0.000557	CcSEcCtD
Lansoprazole—Epistaxis—Methotrexate—lymphatic system cancer	0.000151	0.000555	CcSEcCtD
Lansoprazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000151	0.000555	CcSEcCtD
Lansoprazole—Asthenia—Vincristine—lymphatic system cancer	0.000151	0.000555	CcSEcCtD
Lansoprazole—Diarrhoea—Carmustine—lymphatic system cancer	0.000151	0.000555	CcSEcCtD
Lansoprazole—Nausea—Bleomycin—lymphatic system cancer	0.00015	0.000552	CcSEcCtD
Lansoprazole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00015	0.000549	CcSEcCtD
Lansoprazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000148	0.000541	CcSEcCtD
Lansoprazole—Dizziness—Carmustine—lymphatic system cancer	0.000146	0.000536	CcSEcCtD
Lansoprazole—Diarrhoea—Vincristine—lymphatic system cancer	0.000144	0.000529	CcSEcCtD
Lansoprazole—Hepatitis—Methotrexate—lymphatic system cancer	0.000144	0.000529	CcSEcCtD
Lansoprazole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000143	0.000525	CcSEcCtD
Lansoprazole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000142	0.000522	CcSEcCtD
Lansoprazole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000141	0.000518	CcSEcCtD
Lansoprazole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000141	0.000516	CcSEcCtD
Lansoprazole—Vomiting—Carmustine—lymphatic system cancer	0.000141	0.000515	CcSEcCtD
Lansoprazole—Dizziness—Vincristine—lymphatic system cancer	0.00014	0.000512	CcSEcCtD
Lansoprazole—Rash—Carmustine—lymphatic system cancer	0.000139	0.000511	CcSEcCtD
Lansoprazole—Dermatitis—Carmustine—lymphatic system cancer	0.000139	0.000511	CcSEcCtD
Lansoprazole—Visual impairment—Methotrexate—lymphatic system cancer	0.000139	0.000509	CcSEcCtD
Lansoprazole—Headache—Carmustine—lymphatic system cancer	0.000139	0.000508	CcSEcCtD
Lansoprazole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000136	0.0005	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—lymphatic system cancer	0.000135	0.000494	CcSEcCtD
Lansoprazole—Tinnitus—Methotrexate—lymphatic system cancer	0.000134	0.000493	CcSEcCtD
Lansoprazole—Vomiting—Vincristine—lymphatic system cancer	0.000134	0.000492	CcSEcCtD
Lansoprazole—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000134	0.000491	CcSEcCtD
Lansoprazole—Rash—Vincristine—lymphatic system cancer	0.000133	0.000488	CcSEcCtD
Lansoprazole—Dermatitis—Vincristine—lymphatic system cancer	0.000133	0.000487	CcSEcCtD
Lansoprazole—Headache—Vincristine—lymphatic system cancer	0.000132	0.000485	CcSEcCtD
Lansoprazole—Nausea—Carmustine—lymphatic system cancer	0.000131	0.000482	CcSEcCtD
Lansoprazole—Angiopathy—Methotrexate—lymphatic system cancer	0.000131	0.00048	CcSEcCtD
Lansoprazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000131	0.000479	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—lymphatic system cancer	0.00013	0.000477	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00013	0.000476	CcSEcCtD
Lansoprazole—Rash—Mitoxantrone—lymphatic system cancer	0.00013	0.000475	CcSEcCtD
Lansoprazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00013	0.000475	CcSEcCtD
Lansoprazole—Chills—Methotrexate—lymphatic system cancer	0.000129	0.000474	CcSEcCtD
Lansoprazole—Headache—Mitoxantrone—lymphatic system cancer	0.000129	0.000472	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—lymphatic system cancer	0.000127	0.000467	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—lymphatic system cancer	0.000126	0.000463	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—lymphatic system cancer	0.000126	0.00046	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—lymphatic system cancer	0.000126	0.00046	CcSEcCtD
Lansoprazole—Nausea—Vincristine—lymphatic system cancer	0.000125	0.00046	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000123	0.000451	CcSEcCtD
Lansoprazole—Nausea—Mitoxantrone—lymphatic system cancer	0.000122	0.000448	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—lymphatic system cancer	0.000121	0.000445	CcSEcCtD
Lansoprazole—Vision blurred—Methotrexate—lymphatic system cancer	0.000118	0.000434	CcSEcCtD
Lansoprazole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000116	0.000427	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—lymphatic system cancer	0.000116	0.000425	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—lymphatic system cancer	0.000113	0.000415	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—lymphatic system cancer	0.000113	0.000413	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—lymphatic system cancer	0.000112	0.000412	CcSEcCtD
Lansoprazole—Cough—Methotrexate—lymphatic system cancer	0.00011	0.000401	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—lymphatic system cancer	0.000109	0.000399	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—lymphatic system cancer	0.000107	0.000392	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—lymphatic system cancer	0.000107	0.000392	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—lymphatic system cancer	0.000107	0.000392	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000106	0.000389	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—lymphatic system cancer	0.000106	0.000387	CcSEcCtD
Lansoprazole—Confusional state—Methotrexate—lymphatic system cancer	0.000103	0.000379	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000102	0.000376	CcSEcCtD
Lansoprazole—Infection—Methotrexate—lymphatic system cancer	0.000102	0.000373	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.0001	0.000368	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.0001	0.000368	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—lymphatic system cancer	9.95e-05	0.000365	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—lymphatic system cancer	9.9e-05	0.000363	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—lymphatic system cancer	9.76e-05	0.000358	CcSEcCtD
Lansoprazole—Hypotension—Methotrexate—lymphatic system cancer	9.57e-05	0.000351	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	9.33e-05	0.000342	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—lymphatic system cancer	9.26e-05	0.00034	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—lymphatic system cancer	9.2e-05	0.000337	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—lymphatic system cancer	9.13e-05	0.000335	CcSEcCtD
Lansoprazole—Somnolence—Methotrexate—lymphatic system cancer	9.11e-05	0.000334	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—lymphatic system cancer	9.02e-05	0.000331	CcSEcCtD
Lansoprazole—Decreased appetite—Methotrexate—lymphatic system cancer	8.9e-05	0.000326	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	8.84e-05	0.000324	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—lymphatic system cancer	8.83e-05	0.000324	CcSEcCtD
Lansoprazole—Pain—Methotrexate—lymphatic system cancer	8.76e-05	0.000321	CcSEcCtD
Lansoprazole—Feeling abnormal—Methotrexate—lymphatic system cancer	8.44e-05	0.000309	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	8.38e-05	0.000307	CcSEcCtD
Lansoprazole—Urticaria—Methotrexate—lymphatic system cancer	8.14e-05	0.000298	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—lymphatic system cancer	8.1e-05	0.000297	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—lymphatic system cancer	8.1e-05	0.000297	CcSEcCtD
Lansoprazole—Hypersensitivity—Methotrexate—lymphatic system cancer	7.55e-05	0.000277	CcSEcCtD
Lansoprazole—Asthenia—Methotrexate—lymphatic system cancer	7.35e-05	0.000269	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—lymphatic system cancer	7.25e-05	0.000266	CcSEcCtD
Lansoprazole—Diarrhoea—Methotrexate—lymphatic system cancer	7.01e-05	0.000257	CcSEcCtD
Lansoprazole—Dizziness—Methotrexate—lymphatic system cancer	6.77e-05	0.000248	CcSEcCtD
Lansoprazole—Vomiting—Methotrexate—lymphatic system cancer	6.51e-05	0.000239	CcSEcCtD
Lansoprazole—Rash—Methotrexate—lymphatic system cancer	6.46e-05	0.000237	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—lymphatic system cancer	6.45e-05	0.000237	CcSEcCtD
Lansoprazole—Headache—Methotrexate—lymphatic system cancer	6.42e-05	0.000235	CcSEcCtD
Lansoprazole—Nausea—Methotrexate—lymphatic system cancer	6.08e-05	0.000223	CcSEcCtD
